Staged Annuloplasty Enabling TEER in Extreme Secondary Mitral Regurgitation Authors: Firas Jaly, Holger Priebe-Brämer, Boris Dickmann, Jadwiga Klajn, Klaus Witte, Hans-Jörg Hippe Published: 2026 ABSTRACT AbstractBackgroundSevere secondary mitral regurgitation (SMR) with extreme annular dilatation may preclude transcatheter edge-to-edge repair (TEER).Case SummaryA 71-year-old man with advanced nonischemic cardiomyopathy, severe SMR, and prior cardiac resynchronization therapy with a coronary sinus left ventricular lead was declined for TEER due to a massively dilated mitral annulus (7.4 cm). A staged strategy was undertaken with indirect mitral annuloplasty using the Carillon system, achieving significant annular reduction. The preexisting coronary sinus lead served as a fluoroscopic landmark, facilitating device positioning while minimizing contrast use. Device-related left circumflex artery compression required bailout percutaneous coronary intervention. Following annular reduction, TEER using the MitraClip G4 system was successfully performed, reducing regurgitation to trace. The patient demonstrated marked symptomatic and biomarker improvement with sustained benefit at 1 year.DiscussionThis case highlights a staged transcatheter strategy to overcome anatomical limitations of TEER and expands treatment options in advanced SMR.Take-Home MessagesStaged annuloplasty may enable TEER in otherwise ineligible patients. Cardiac resynchronization therapy coronary sinus leads do not preclude Carillon implantation and may facilitate the procedure, whereas coronary compression in selected cases can be managed safely with percutaneous coronary intervention.Key words: cardiac resynchronization therapy, chronic heart failure, valve repair Background Secondary mitral regurgitation (SMR) in the context of advanced left ventricular remodeling remains associated with substantial morbidity and mortality despite contemporary guideline-directed medical therapy.1 Transcatheter edge-to-edge repair (TEER) has emerged as an established therapeutic option in carefully selected patients, with randomized trials demonstrating symptomatic and prognostic benefit when applied within appropriate anatomical and clinical criteria.2,3 However, procedural success is highly dependent on mitral valve anatomy, particularly annular dimensions, leaflet tethering, and reduced leaflet coaptation.4 In patients with extreme annular dilatation and large coaptation gaps, TEER is often not feasible or unlikely to achieve durable results.5 As a consequence, many symptomatic patients remain without interventional treatment options. Indirect mitral annuloplasty using coronary sinus–based systems offers a complementary approach by reducing annular dimensions and improving leaflet coaptation,6 thereby potentially converting anatomically unsuitable patients into candidates for TEER as part of a staged strategy. The presence of a preexisting cardiac resynchronization therapy (CRT) system with a coronary sinus left ventricular pacing lead introduces additional procedural considerations and has traditionally raised concerns regarding feasibility, device interaction, and lead stability during annuloplasty. However, it may also provide procedural advantages by serving as a fluoroscopic landmark for coronary sinus navigation and facilitating device positioning, particularly in patients in whom contrast minimization is desirable. This case illustrates how a staged transcatheter approach combining indirect mitral annuloplasty and TEER can overcome anatomical limitations in severe SMR, while also demonstrating that the presence of a coronary sinus pacing lead does not preclude—and may even facilitate—successful annuloplasty. Patient Presentation A 71-year-old man with advanced heart failure secondary to dilated nonischemic cardiomyopathy was referred for evaluation of severe secondary (functional) mitral regurgitation. Despite optimal guideline-directed medical therapy and prior cardiac resynchronization therapy with defibrillator (CRT-D) implantation 12 years earlier (Medtronic Brava device with an Attain Ability 4,196 left ventricular pacing lead), he had experienced recurrent episodes of heart failure decompensation. His medical history was notable for chronic atrial fibrillation with prior catheter ablation (currently in stable sinus rhythm), arterial hypertension, and chronic kidney disease. The patient reported incapacitating, progressive exertional dyspnea, with symptoms consistent with NYHA functional class IIIb, resulting in a marked limitation of daily activities and rendering him unable to work. On clinical examination, there were signs of chronic heart failure, including mild peripheral edema and a pansystolic murmur best heard at the cardiac apex. Owing to the extreme annular dimensions and advanced ventricular remodeling, the patient had previously been declined for TEER at several high-volume centers. Comprehensive transthoracic and transesophageal echocardiography confirmed severe secondary mitral regurgitation. Quantitative assessment demonstrated Grade IV° mitral regurgitation with an effective regurgitant orifice area of 0,68 cm2, a regurgitant volume of 71 mL, and a vena contracta width of 12 mm. The coaptation gap measured approximately 11 mm in the central A2/P2 region. Posterior leaflet tethering height was 9 mm, consistent with advanced left ventricular remodeling. Left ventricular end-diastolic and end-systolic volumes were markedly increased. The maximal mitral annular diameter measured 7.4 cm, exceeding the recommended anatomical thresholds for TEER feasibility according to contemporary guideline criteria and trial evidence.7,8 Electrocardiography demonstrated sinus rhythm without acute abnormalities. Laboratory evaluation revealed chronically impaired and progressively worsening renal function, with a serum creatinine level of 3.2 mg/dL, and an estimated glomerular filtration rate of 20 mL/min/1.73 m2. N-terminal pro–B-type natriuretic peptide (NT-proBNP) was markedly elevated at 28,196 pg/mL. Interrogation of the CRT-D system demonstrated appropriate device function, with a biventricular pacing percentage of 98%. The left ventricular pacing lead exhibited stable electrical parameters, with a capture threshold of 1.0 V at 0.5 ms and an impedance of 475 Ω, with a battery longevity of approximately 2 years. Invasive coronary angiography once again excluded the presence of obstructive coronary artery disease. Collectively, these findings indicated that direct TEER would be technically challenging and likely ineffective in the absence of prior annular reduction. Heart Team Decision and Staged Interventional Strategy The marked anatomical complexity of the mitral valve rendered the patient unsuitable for upfront TEER. In particular, the presence of extreme annular dilatation (maximum diameter 7.4 cm), a large central coaptation defect, and significant leaflet tethering represented well-established predictors of procedural failure, including inability to achieve adequate leaflet grasping and a high likelihood of residual regurgitation. Collectively, these features placed the patient outside currently accepted anatomical criteria for TEER based on contemporary guideline recommendations and trial experience. In accordance with European Society of Cardiology guidelines, the case was discussed within a multidisciplinary Heart Team. Surgical intervention was deemed prohibitive due to severely impaired left ventricular function, advanced ventricular remodeling, and the overall comorbidity burden. Transcatheter mitral valve replacement was also considered; however, the extreme annular dimensions exceeded the anatomical limits of currently available devices, precluding this option. Given the absence of conventional therapeutic options, a staged transcatheter strategy was pursued. The rationale for this approach was to modify the underlying annular geometry and improve leaflet coaptation prior to definitive repair. Indirect mitral annuloplasty using a coronary sinus–based system (Carillon Mitral Contour System, Cardiac Dimensions) was selected as the initial step, with the aim of reducing annular dimensions, decreasing leaflet malcoaptation, and thereby converting an anatomically unsuitable valve into one amenable to TEER. This strategy was based on the concept that targeted annular reduction can improve leaflet approximation and reduce coaptation gap size, thereby enhancing the likelihood of successful leaflet grasping and durable repair. Following annuloplasty, reassessment of mitral valve geometry was planned to determine feasibility for subsequent TEER. Indirect Mitral Annuloplasty The procedure was performed via right internal jugular venous access with careful minimization of contrast due to advanced chronic kidney disease. The preexisting coronary sinus left ventricular pacing lead was intentionally used as a fluoroscopic landmark, facilitating coronary sinus cannulation and device positioning while reducing contrast requirements. The presence of the lead did not interfere with device delivery. Following cannulation, a usable coronary sinus length of 10 cm was confirmed. A 60-mm device (9-mm distal and 18-mm proximal anchors) was deployed, achieving substantial annular cinching of approximately 5 cm. Prior to final release, coronary angiography demonstrated significant compression of the left circumflex artery (posterolateral branch) with reduced TIMI flow grade I-II, unresponsive to intracoronary nitroglycerin. Given the lack of alternative treatment options, the device was released and percutaneous coronary intervention (PCI) was performed. Using an EBU 4.0 guiding catheter, the vessel was wired and predilated (2.5 × 12 mm semi-compliant balloon), followed by implantation of a 2.25 × 18 mm drug-eluting stent, restoring TIMI III flow. Post-Annuloplasty Assessment Echocardiography demonstrated marked annular reduction (7.4 → 5.5 cm in 4-chamber view; 6.8 → 4.8 cm in 2-chamber view). Mitral regurgitation improved from Grade IV to III with reduced leaflet malcoaptation and a more eccentric jet. Procedural time was 54 minutes, with 95 mL contrast used. CRT-D interrogation showed unchanged lead parameters, with no evidence of device interaction. Renal function remained stable. Dual antithrombotic therapy (apixaban and clopidogrel) was prescribed for 3 months following PCI. Staged TEER At 6 weeks, repeat imaging confirmed sustained annular reduction and anatomical suitability for TEER. Using the MitraClip G4 system (Abbott), an XTW clip was deployed at the A2/P2 segment under transesophageal echocardiographic guidance. This resulted in near-complete elimination of mitral regurgitation (grade III to trace) with a mean transmitral gradient of 2 to 3 mm Hg. Follow-Up The patient demonstrated rapid symptomatic improvement, with NYHA functional class improving from IIIb to I–II and return to work in a sedentary capacity. Left ventricular ejection fraction remained unchanged at 18%; however, the absence of further decompensations suggested meaningful hemodynamic benefit. NT-proBNP decreased from 28,196 to 4,628 pg/mL at 6 months. Renal function improved markedly (creatinine 3.2 → 1.3 mg/dL; estimated glomerular filtration rate 20 → 58 mL/min/1.73 m2), consistent with reversal of cardiorenal syndrome. No bleeding events or major adverse cardiovascular events occurred. At 1-year follow-up, the patient remained clinically stable with sustained symptomatic improvement, mild residual mitral regurgitation, and no heart failure hospitalizations or device-related complications. Discussion This case demonstrates 3 clinically relevant insights. First, extreme mitral annular dilatation should not be considered an absolute contraindication to transcatheter therapy. Although current evidence and guideline recommendations support TEER in anatomically suitable patients,9 those with excessive annular dimensions and impaired leaflet coaptation are frequently excluded.10 In this case, indirect mitral annuloplasty achieved substantial annular reduction, improved leaflet coaptation, and enabled subsequent successful TEER. Second, coronary sinus–based annuloplasty in patients with preexisting CRT systems appears not only feasible but may be technically facilitated by the presence of a coronary sinus pacing lead. Although concerns regarding mechanical interaction or lead instability have limited broader adoption, no adverse effects on lead function or position were observed. Importantly, the coronary sinus lead served as a valuable fluoroscopic landmark, facilitating coronary sinus access and device positioning while allowing reduction of contrast use in a patient with advanced renal impairment. This observation has practical implications for procedural planning in a growing population of patients with CRT devices and SMR. Third, coronary artery compression is a recognized complication of indirect mitral annuloplasty, reflecting the close anatomical relationship between the coronary sinus and the left circumflex artery. Reported risk factors include a short distance between these structures, significant annular dilation, and vessel proximity along the atrioventricular groove. Careful intraprocedural angiographic assessment during device tensioning is therefore essential. In the present case, despite identification of significant compression, the absence of alternative treatment options and the feasibility of complete revascularization supported continuation of the procedure with planned bailout PCI. This underscores the importance of individualized decision making and highlights that, in selected patients, bailout PCI may allow safe completion of the procedure. Following completion of the staged procedure, the patient experienced marked clinical improvement, with substantial reduction in symptoms (NYHA functional class), a significant decrease in NT-proBNP levels, and improvement in renal function. Notably, left ventricular systolic function remained unchanged, reflecting the presence of advanced myocardial remodeling in the setting of severe ventricular dilatation. This observation underscores that symptomatic benefit in SMR may occur independently of reverse remodeling. In this context, the concept of disproportionate mitral regurgitation may be particularly relevant, whereby the severity of regurgitation exceeds that expected for the degree of left ventricular dilatation. In such cases, reduction of regurgitant volume can lead to meaningful increases in forward stroke volume and clinical improvement, even in the absence of measurable recovery in ventricular function. This may be especially applicable in patients with extreme ventricular enlargement, where structural myocardial recovery is limited but optimization of forward cardiac output remains beneficial. Overall, this case supports a patient-centered, Heart Team–guided approach and illustrates how combining transcatheter modalities can overcome anatomical limitations and expand treatment options in advanced SMR. Conclusion A staged transcatheter approach combining indirect mitral annuloplasty and TEER can overcome anatomical limitations in severe SMR and expand treatment options in otherwise ineligible patients. The presence of a coronary sinus CRT lead does not preclude—and may facilitate—annuloplasty by improving procedural guidance and enabling contrast minimization. In selected cases, procedure-related coronary artery compression can be effectively managed with bailout PCI. Staged Transcatheter Approach, From Initial Indirect Mitral Annuloplasty to Subsequent TEER, Highlighting the Temporal Sequence and Clinical Outcome CRT = cardiac resynchronization therapy; LVEF = left ventricular ejection fraction; MR = mitral regurgitation; PCI = percutaneous coronary intervention; TEER = transcatheter edge-to-edge repair. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Take-Home Messages •Staged annuloplasty may enable TEER in otherwise ineligible patients. Staged annuloplasty may enable TEER in otherwise ineligible patients. •CRT coronary sinus leads do not preclude Carillon implantation and may facilitate the procedure, whereas coronary compression in selected cases can be managed safely with PCI. CRT coronary sinus leads do not preclude Carillon implantation and may facilitate the procedure, whereas coronary compression in selected cases can be managed safely with PCI. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental videos, please see the online version of this paper. Appendix Video 1 Transthoracic Echocardiography (TTE), Apical 4-Chamber View, Demonstrating Dilated Cardiomyopathy (DCM) with Severe (Grade IV) Secondary Mitral Regurgitation (MR) due to Marked Annular Dilatation Video 2 TTE Following Carillon Device Implantation, Demonstrating a Significant Reduction in Mitral Annular Dimensions Video 3 TTE, Apical 4-Chamber View After Carillon Implantation, Showing a More Eccentric Regurgitant Jet with a Mild Reduction in MR Severity (Grade IV to Grade III) Video 4 Transesophageal Echocardiography (TEE) Following Carillon Implantation, Demonstrating Significant Annular Reduction with Persistent, Now Eccentric, Grade III MR Video 5 TEE After Staged Indirect Mitral Annuloplasty (IMA) and Transcatheter Edge-to-Edge Repair (TEER), Demonstrating Trace Residual MR Video 6 Fluoroscopic Image After Carillon Device Implantation Showing Significant Compression of the Left Circumflex Artery Video 7 Fluoroscopic Image Demonstrating Percutaneous Coronary Intervention (PCI) of the Left Circumflex Artery Video 8 Fluoroscopic Image Showing the Final Result After PCI of the Left Circumflex Artery with Restoration of TIMI III flow Video 9 Three-Dimensional Transesophageal Echocardiographic Reconstruction of the Mitral Valve with Color Doppler at Baseline, Demonstrating Severe Secondary Mitral Regurgitation with a Broad Central Jet Extending Across the Coaptation Line, Consistent with Marked Leaflet Malcoaptation References Associated Data Supplementary Materials Video 1 Transthoracic Echocardiography (TTE), Apical 4-Chamber View, Demonstrating Dilated Cardiomyopathy (DCM) with Severe (Grade IV) Secondary Mitral Regurgitation (MR) due to Marked Annular Dilatation Video 2 TTE Following Carillon Device Implantation, Demonstrating a Significant Reduction in Mitral Annular Dimensions Video 3 TTE, Apical 4-Chamber View After Carillon Implantation, Showing a More Eccentric Regurgitant Jet with a Mild Reduction in MR Severity (Grade IV to Grade III) Video 4 Transesophageal Echocardiography (TEE) Following Carillon Implantation, Demonstrating Significant Annular Reduction with Persistent, Now Eccentric, Grade III MR Video 5 TEE After Staged Indirect Mitral Annuloplasty (IMA) and Transcatheter Edge-to-Edge Repair (TEER), Demonstrating Trace Residual MR Video 6 Fluoroscopic Image After Carillon Device Implantation Showing Significant Compression of the Left Circumflex Artery Video 7 Fluoroscopic Image Demonstrating Percutaneous Coronary Intervention (PCI) of the Left Circumflex Artery Video 8 Fluoroscopic Image Showing the Final Result After PCI of the Left Circumflex Artery with Restoration of TIMI III flow Video 9 Three-Dimensional Transesophageal Echocardiographic Reconstruction of the Mitral Valve with Color Doppler at Baseline, Demonstrating Severe Secondary Mitral Regurgitation with a Broad Central Jet Extending Across the Coaptation Line, Consistent with Marked Leaflet Malcoaptation